|Day Low/High||84.51 / 85.53|
|52 Wk Low/High||64.18 / 86.72|
Wall Street's first glimpse at the second quarter.
There are five over-tenured directors and four directors with whom CEO Ginni Rometty works with outside of the company, according to BoardEx.
Earnings help boost markets as D.C. isn't counted on for much of anything. Portfolio action (it was a busy week) includes a new position and a downgrade.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
We're selling our shares in Walgreens as our bullish thesis has lost its luster.
We're adding Nvidia, removing TMO and Six Flags, plus 2 updates.
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
The FDA has given priority review designation for abemaciclib.
Partnering with Lilly and Boehringer Ingelheim, Don Francisco encourages Hispanic communities to learn the facts about diabetes management
Jobs report and Fed minutes highlight a short week. In the portfolio, we add one name and downgrade another.
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
Lilly will provide up to $52 million to fund life science research over five years
Patients Who Create An Account on Leading Prescription Drug Savings Platform Blink Health Will Receive a Free, One-Year Supply of Three Most Prescribed Generic Type-2 Diabetes Medications: Metformin, Glipizide and Pioglitazone --Until Funds Are Exhausted
This U.S. diabetes camp support program has provided speakers, scholarships, medicines and educational materials since 2001
New facility and improved technology capabilities part of $850 million U.S. capital investment for 2017
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.